Cirrhosis Deprescribing Interviews Identify Barriers, Not Proof That Stopping Benzodiazepines Prevents Encephalopathy

Interview findings can explain why medication changes are difficult without measuring their clinical benefit.

What the supplied research shows

Researchers interviewed eight patients with cirrhosis and fourteen clinicians about medicines associated with hepatic encephalopathy, including benzodiazepines. Patients described concern about symptoms returning and wanted clearer education. Clinicians identified uncertainty about safe deprescribing, limited time and responsibility being deferred among providers. Participants supported additional help from pharmacists or nurses.

What it cannot establish

This was a qualitative study of twenty-two people, not a randomized withdrawal trial. It did not estimate the reduction in encephalopathy produced by stopping a particular medicine, establish a universal taper, or compare every alternative. Views from selected participants may not represent other care settings.

Forensic interpretation and case review

For a case involving liver disease and altered consciousness, separate the medicine’s plausible contribution from the actual clinical course. Review liver status, previous encephalopathy, treatment indication, dose changes and communication between prescribers. The interviews may support questions about coordination and informed discussion, but they cannot establish that immediate cessation would have prevented an event. A report should also avoid treating a patient’s concern about symptom recurrence as evidence of misuse. The study concerns decision-making barriers, not a determination of fault in an individual case.

Source and related reading

Source: supplied full-text paper, PMC8259255. Research findings are paraphrased; the case-review discussion is an interpretation of that evidence.

Related: A Palliative-Care Cohort Did Not Detect a Benzodiazepine–Delirium Association.